"After 23 years of screening, the reduction in breast cancer mortality in women aged 50 or more associated with screening ranges from 0 to 5%," the researchers concluded.
The outcome measures observed were the costs of screening, the reduction in costs to the INHS as a result of reduced morbidity and mortality and the improvement in health outcomes measured in QALYs, in line with standard practice in Italian cost-effectiveness analyses [ 17].
For women over 50 years of age at entry to a trial, the reduction in breast cancer mortality in those invited to screening is approx. 25%, and in women who are screened the reduction is approx.33% [ 1].
Measures of the success of a genetic screening program include uptake within the target population, percentage of the target population offered access to screening, the level of informed consent among individuals screened, the reduction of target disease incidence over time through the uptake of assisted reproductive technologies, and selective pregnancy termination and economic outcomes.
In conclusion, in studies on breast cancer screening the mortality reduction ranges from 38 to 70% [ 6– 12].
After lengthy methodological controversy over the efficacy of screening for LC, in recent years the results of observational screening with chest computed tomography (CT) in heavy smokers has shown a significant reduction of LC mortality [ 8]; with chest X-ray (CXR) screening the LC mortality reduction was less pronounced but still significant [ 9, 10].
A set of fusion proteins consisting of glutathione S-transferase linked to the N-terminus of putative dehydrogenases produced by baker's yeast (Saccharomyces cerevisiae) was screened for the reduction of ethyl 2-oxo-4-phenylbutyrate in the presence of NADH and NADPH.
Secondly, a panel of ketoreductases (KREDs), which are known to be highly active and selective for reduction of a range of carbonyl compounds, 18 were screened for the reduction of the achiral dialdehyde 1 c.
These factors could promote the glucuronidation of myricetin considering that under both filter screens the reduction in aglycon levels correlated with the increase in the glucuronidated form.
Unfortunately, there is a lack of conclusive evidence of the value of PSA screening in the reduction of mortality; two randomized controlled PSA screening trials, one in Europe and the other in the US, recently reported disparate results for the effect of PSA testing on prostate cancer mortality [ 2, 3].
Nevertheless, a model predicting outcomes using data from participants in the Mayo CT screening study indicated a 28% reduction in lung cancer mortality at 6 years due to screening, although the reduction in all-cause mortality was only 2% at 15 years due to increased mortality from non-lung cancer causes associated with smoking.
